Spectranetics Unfazed By Study On Laser Use For In-Stent Restenosis
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics is confident that clinical trials for the firm's CVX-300 excimer laser will demonstrate the device to be effective in treating in-stent restenosis despite unfavorable results reported in a recently completed independent study.
You may also be interested in...
PTCA Catheter Downclassification Carries Unresolved Safety Issues - Panel
Postmarket surveillance requirements should be part of any decision to downclassify percutaneous transluminal coronary angioplasty (PTCA) balloon catheters from Class III to Class II, according to FDA's Circulatory System Devices Panel.
PTCA Catheter Downclassification Carries Unresolved Safety Issues - Panel
Postmarket surveillance requirements should be part of any decision to downclassify percutaneous transluminal coronary angioplasty (PTCA) balloon catheters from Class III to Class II, according to FDA's Circulatory System Devices Panel.
Spectranetics To Study Laser-Assisted In-Stent Restenosis Therapy
Spectranetics is preparing to evaluate a laser-assisted treatment for in-stent restenosis that could offer an alternative to coronary artery bypass surgery.